Xibrom Related Published Studies
Well-designed clinical trials related to Xibrom (Bromfenac Ophthalmic)
Comparison of efficacy of bromfenac sodium 0.1% ophthalmic solution and fluorometholone 0.02% ophthalmic suspension for the treatment of allergic conjunctivitis. [2009.06]
Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery. [2009.05]
Topical bromfenac 0.09% vs. ketorolac 0.4% for the control of pain, photophobia, and discomfort following PRK. [2009.02]
Ocular pharmacokinetics of a single dose of bromfenac sodium ophthalmic solution 0.1% in human aqueous humor. [2008.12]
Comparison of ketorolac 0.4% and bromfenac 0.09% at trough dosing: aqueous drug absorption and prostaglandin E2 levels. [2008.09]
In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. [2007.09]
Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation. [2007.09]
Effects of an opioid (oxycodone/paracetamol) and an NSAID (bromfenac) on driving ability, memory functioning, psychomotor performance, pupil size, and mood. [2006.06]
Other research related to Xibrom (Bromfenac Ophthalmic)
Ophthalmic utility of topical bromfenac, a twice-daily nonsteroidal anti-inflammatory agent. [2009.10]
Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. [2009.09.02]
Aqueous prostaglandin E(2) of cataract patients at trough ketorolac and bromfenac levels after 2 days dosing. [2009.06]
Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery. [2009.01.30]
24-hour evaluation of the ocular distribution of (14)c-labeled bromfenac following topical instillation into the eyes of New Zealand white rabbits. [2008.08]
The systemic safety of bromfenac ophthalmic solution 0.09%. [2007.12]
Corneal melting and perforation in Stevens Johnson syndrome following topical bromfenac use. [2007.09]
Bromfenac Ophthalmic Solution 0.09% (Xibrom) for Postoperative Ocular Pain and Inflammation. [2007.04.18]
Topical bromfenac sodium for long-term management of vernal keratoconjunctivitis. [2007]
Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. [2006.06]
A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience. [2006.04]
Other possibly related research studies
Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: a case/noncase analysis of spontaneous reports. [2006.08]
Three cases of corneal melting after instillation of a new nonsteroidal anti-inflammatory drug. [2006.02]
Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac. [2006.02]
Effects of topical anti-inflammatory agents in a botulinum toxin B-induced mouse model of keratoconjunctivitis sicca. [2007.02]
Effects of nonsteroidal ophthalmic drops on epithelial healing and pain in patients undergoing bilateral photorefractive keratectomy (PRK). [2007.11]
Topical ocular delivery of NSAIDs. [2008.06]
Cyclooxygenase (COX)-inhibiting drug reduces HSV-1 reactivation in the mouse eye model. [2009.03]
|
